Moderate alcohol consumption generally does not interfere with the effectiveness of sildenafil, but excessive intake can exacerbate blood-pressure-lowering effects and may diminish the ability to achieve an erection. It is safest to limit alcohol to a moderate amount when planning sexual activity.
The pharmacological effect typically lasts 4 to 6 hours after ingestion, with the peak benefit occurring 1-2 hours post-dose. Sexual activity should be attempted within this window for optimal results.
Men with well-controlled hypertension may use sildenafil safely, but uncontrolled high blood pressure (systolic > 180 mmHg or diastolic > 100 mmHg) is a contraindication. Blood pressure should be measured and stabilized before initiating therapy.
A prolonged erection (priapism) is a medical emergency. Seek immediate care at an emergency department or call 999. Prompt treatment is essential to prevent permanent tissue damage.
Sildenafil can be taken together with many antihypertensives, but caution is advised when combined with alpha-blockers or nitrates. Discuss all blood-pressure medicines with your prescriber to avoid additive hypotensive effects.
It is not mandatory, but a high-fat meal can delay the onset of action by up to an hour. Taking the tablet with a light meal or on an empty stomach provides more predictable timing.
Current evidence does not indicate that sildenafil adversely affects male fertility or sperm parameters when used at therapeutic doses for erectile dysfunction.
Splitting tablets is not officially recommended because it may result in uneven dosing. If a lower dose is required, a prescriber should issue a prescription for a product that is manufactured in a lower strength.
Sildenafil does not cause physiological dependence. Psychological reliance on medication for sexual performance can occur; counseling or sexual therapy may be beneficial in such cases.
Keep the medication in its original packaging, store it at temperatures below 30 °C, and protect it from moisture. Carry it in hand luggage to avoid temperature extremes in checked baggage, and retain the prescription label for customs clearance if required.
Eriacta is a prescription-only medication (POM) available in the United Kingdom for the treatment of erectile dysfunction (ED). Each tablet contains 100 mg of sildenafil, the same active ingredient found in the generic drug sildenafil citrate. The product is supplied as an oral pill and is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). Eriacta belongs to the therapeutic class of phosphodiesterase-5 (PDE5) inhibitors, which act on the nitric-oxide pathway to facilitate penile erection in response to sexual stimulation.
Sildenafil selectively inhibits the enzyme phosphodiesterase-5 (PDE5), which normally breaks down cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. By blocking PDE5, sildenafil allows cGMP to accumulate, leading to:
The onset of action typically occurs within 30-60 minutes, with the peak effect around 1-2 hours after ingestion. The pharmacological effect diminishes after about 4-6 hours, which defines the window in which sexual activity is most likely to be successful.
Eriacta is approved by the MHRA for the treatment of erectile dysfunction in adult men. ED is defined as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance. Sildenafil addresses the vascular component of ED and is effective for men with:
Prescription of Eriacta should follow a clinical assessment that confirms the diagnosis of ED and excludes contraindications.
Sildenafil is also approved in the United Kingdom (under the brand name Revatio) for the management of pulmonary arterial hypertension. The drug improves exercise capacity by dilating pulmonary vessels, thereby reducing right-ventricular afterload. When used for PAH, dosing and monitoring differ from the ED indication.
Regulatory status: Use of Eriacta for PAH is off-label because the product is licensed specifically for erectile dysfunction. Off-label prescribing must be justified by clinical evidence and undertaken by a specialist with the patient’s informed consent.
Limited case series have examined sildenafil for the prevention of high-altitude pulmonary edema because of its pulmonary vasodilatory effects. Evidence remains preliminary, and the use is not recommended outside a research setting.
Disclaimer: Off-label applications must be supervised by a qualified health professional, who will weigh potential benefits against risks.
When any of the above conditions are present, a clinician must carefully assess the risk-benefit profile before prescribing Eriacta.
These effects are usually transient and resolve without medical intervention. If they persist or become bothersome, the prescriber may consider dose adjustment or an alternative therapy.
| Interaction Type | Examples | Clinical Impact | ||-|--| | Major | Nitrates (e.g., glyceryl trinitrate) | Additive vasodilation → life-threatening hypotension | | Major | Guanylate cyclase stimulators (e.g., riociguat) | Synergistic vasodilation | | Moderate | Alpha-blockers (e.g., tamsulosin) | May cause symptomatic hypotension; monitor blood pressure | | Moderate | CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) | Increase sildenafil plasma levels → higher risk of side effects | | Moderate | CYP3A4 inducers (e.g., rifampicin, carbamazepine) | Decrease plasma levels → reduced efficacy |
Patients should provide a complete medication list, including over-the-counter drugs, herbal supplements, and recreational substances, to their prescriber.
This article provides educational information about Eriacta and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
